Menu

Close

Sign InSign Out

Products

Order

Order

See all

Co-pay cards & patient savings offers

Materials

Samples*

Hospital products

Vaccines, biologics & small-molecule medicines**​​​​​​​​​​​​​​​​​​​​​

Patient Assistance

Patient Assistance

Find available assistance programs

Go to Patient Assistance

Pfizer Oncology Together

Pfizer RxPathways

Explore content

Explore content

Explore more content

Events

Videos

Materials

Contact

Contact

See all Contact

Pfizer corporate

Ask a question

Menu

Close

About

About

IBRANCE experience

Guidelines

Mechanism of action

Dosing & Monitoring

Dosing & Monitoring

Dosing and administration

Monitoring

Recommended dose modifications for IBRANCE

What you need to know about IBRANCE tablets

Efficacy

​​​​​​​Efficacy

IBRANCE + aromatase inhibitor

Primary endpoint

Secondary endpoints

Updated analyses

Subgroup analyses

IBRANCE + fulvestrant​​​​​​​

Primary endpoint

Secondary endpoints

Updated analyses

Subgroup analyses

Safety Data

Safety Data

​​​​​​​IBRANCE + aromatase inhibitor

Adverse reactions

Discontinuations and dose reductions

Neutropenia and lab abnormalities

Warnings and Precautions

​​​​​​​IBRANCE + fulvestrant

Adverse reactions

Discontinuations and dose reductions

Neutropenia and lab abnormalities

Warnings and Precautions

Real-World Evidence

​​​​​​​Real-World Evidence​​​​​​​

Introduction

Clinical trial summary

Real-world study design

Real-world study patient characteristics

Real-world effectiveness

Support & Order

​​​​​​​ Support & Order

Events

Videos

Materials

Coverage and access

Personalized patient support

  • Prescribing Information for Capsules
  • Prescribing Information for Tablets
  • Patient Site
  • Medical Information

  • About

    IBRANCE experience

    Evaluated in a broad range of patients

         DFI=disease-free interval; ER=estrogen receptor; ET=endocrine therapy.

       *PALOMA-2 was a 2:1 randomized, double-blind, Phase 3 trial of postmenopausal women with ER+/HER2- mBC with no prior treatment in the metastatic setting (N=666). IBRANCE 125 mg PO once daily was taken 3 weeks on, 1 week off + letrozole 2.5 mg PO once daily vs placebo + letrozole.1

        PALOMA-3 was a 2:1 randomized, double-blind, Phase 3 trial of women with HR+/HER2- mBC who progressed on or after endocrine therapy in the adjuvant or metastatic setting (N=521). IBRANCE 125 mg PO once daily was taken 3 weeks on, 1 week off + fulvestrant 500 mg IM on Days 1, 15, 29, and monthly thereafter vs placebo + fulvestrant.2

    In-practice experience

    Experience with IBRANCE in HR+/HER2- mBC has grown rapidly since its FDA approval in 2015.

    Estimated data as of November 2020.3


    References:
    1. Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925-1936.
    2. Turner NC, Ro J, André F, et al; PALOMA3 Study Group. Palbociclib in hormone-receptor–positive advanced breast cancer. N Engl J Med. 2015;373(3):209-219.
    3. Data on file. Pfizer Inc., New York, NY.

    Connects patients and caregivers with an IBRANCE Patient or Caregiver Ambassador for private one-on-one phone conversations

    Learn more

    Delivers insights, facts, and resources to help patients throughout treatment

    Learn more

    Neutropenia was the most frequently reported adverse reaction in PALOMA-2 (80%) and PALOMA-3 (83%). In PALOMA-2, Grade 3 (56%) or 4 (10%) decreased neutrophil counts were reported in patients receiving IBRANCE plus letrozole. In PALOMA-3, Grade 3 (55%) or Grade 4 (11%) decreased neutrophil counts were reported in patients receiving IBRANCE plus fulvestrant. Febrile neutropenia has been reported in 1.8% of patients exposed to IBRANCE across PALOMA-2 and PALOMA-3. One death due to neutropenic sepsis was observed in PALOMA-3. Inform patients to promptly report any fever.

    Monitor complete blood count prior to starting IBRANCE, at the beginning of each cycle, on Day 15 of first 2 cycles and as clinically indicated. Dose interruption, dose reduction, or delay in starting treatment cycles is recommended for patients who develop Grade 3 or 4 neutropenia.

    Severe, life-threatening, or fatal interstitial lung disease (ILD) and/or pneumonitis can occur in patients treated with CDK4/6 inhibitors, including IBRANCE when taken in combination with endocrine therapy. Across clinical trials (PALOMA-1, PALOMA-2, PALOMA-3), 1.0% of IBRANCE-treated patients had ILD/pneumonitis of any grade, 0.1% had Grade 3 or 4, and no fatal cases were reported. Additional cases of ILD/pneumonitis have been observed in the post-marketing setting, with fatalities reported.

    Monitor patients for pulmonary symptoms indicative of ILD/pneumonitis (e.g., hypoxia, cough, dyspnea). In patients who have new or worsening respiratory symptoms and are suspected to have developed pneumonitis, interrupt IBRANCE immediately and evaluate the patient. Permanently discontinue IBRANCE in patients with severe ILD or pneumonitis.

    Based on the mechanism of action, IBRANCE can cause fetal harm. Advise females of reproductive potential to use effective contraception during IBRANCE treatment and for at least 3 weeks after the last dose. IBRANCE may impair fertility in males and has the potential to cause genotoxicity. Advise male patients to consider sperm preservation before taking IBRANCE. Advise male patients with female partners of reproductive potential to use effective contraception during IBRANCE treatment and for 3 months after the last dose. Advise females to inform their healthcare provider of a known or suspected pregnancy. Advise women not to breastfeed during IBRANCE treatment and for 3 weeks after the last dose because of the potential for serious adverse reactions in nursing infants. 

    The most common adverse reactions (≥10%) of any grade reported in PALOMA-2 for IBRANCE plus letrozole vs placebo plus letrozole were neutropenia (80% vs 6%), infections (60% vs 42%), leukopenia (39% vs 2%), fatigue (37% vs 28%), nausea (35% vs 26%), alopecia (33% vs 16%), stomatitis (30% vs 14%), diarrhea (26% vs 19%), anemia (24% vs 9%), rash (18% vs 12%), asthenia (17% vs 12%), thrombocytopenia (16% vs 1%), vomiting (16% vs 17%), decreased appetite (15% vs 9%), dry skin (12% vs 6%), pyrexia (12% vs 9%), and dysgeusia (10% vs 5%).

    The most frequently reported Grade ≥3 adverse reactions (≥5%) in PALOMA-2 for IBRANCE plus letrozole vs placebo plus letrozole were neutropenia (66% vs 2%), leukopenia (25% vs 0%), infections (7% vs 3%), and anemia (5% vs 2%).

    Lab abnormalities of any grade occurring in PALOMA-2 for IBRANCE plus letrozole vs placebo plus letrozole were decreased WBC (97% vs 25%), decreased neutrophils (95% vs 20%), anemia (78% vs 42%), decreased platelets (63% vs 14%), increased aspartate aminotransferase (52% vs 34%), and increased alanine aminotransferase (43% vs 30%). 

    The most common adverse reactions (≥10%) of any grade reported in PALOMA-3 for IBRANCE plus fulvestrant vs placebo plus fulvestrant were neutropenia (83% vs 4%), leukopenia (53% vs 5%), infections (47% vs 31%), fatigue (41% vs 29%), nausea (34% vs 28%), anemia (30% vs 13%), stomatitis (28% vs 13%), diarrhea (24% vs 19%), thrombocytopenia (23% vs 0%), vomiting (19% vs 15%), alopecia (18% vs 6%), rash (17% vs 6%), decreased appetite (16% vs 8%), and pyrexia (13% vs 5%).

    The most frequently reported Grade ≥3 adverse reactions (≥5%) in PALOMA-3 for IBRANCE plus fulvestrant vs placebo plus fulvestrant were neutropenia (66% vs 1%) and leukopenia (31% vs 2%). 

    Lab abnormalities of any grade occurring in PALOMA-3 for IBRANCE plus fulvestrant vs placebo plus fulvestrant were decreased WBC (99% vs 26%), decreased neutrophils (96% vs 14%), anemia (78% vs 40%), decreased platelets (62% vs 10%), increased aspartate aminotransferase (43% vs 48%), and increased alanine aminotransferase (36% vs 34%). 

    Avoid concurrent use of strong CYP3A inhibitors. If patients must be administered a strong CYP3A inhibitor, reduce the IBRANCE dose to 75 mg. If the strong inhibitor is discontinued, increase the IBRANCE dose (after 3-5 half-lives of the inhibitor) to the dose used prior to the initiation of the strong CYP3A inhibitor. Grapefruit or grapefruit juice may increase plasma concentrations of IBRANCE and should be avoided. Avoid concomitant use of strong CYP3A inducers. The dose of sensitive CYP3A substrates with a narrow therapeutic index may need to be reduced as IBRANCE may increase their exposure.

    For patients with severe hepatic impairment (Child-Pugh class C), the recommended dose of IBRANCE is 75 mg. The pharmacokinetics of IBRANCE have not been studied in patients requiring hemodialysis

    Please see full Prescribing Information for IBRANCE capsules and tablets .

    IBRANCE (palbociclib) 125 mg capsules and tablets are indicated for the treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer (mBC) in combination with:

    • an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men, or
    • fulvestrant in patients with disease progression following endocrine therapy

    INDICATIONS

    IBRANCE (palbociclib) 125 mg capsules and tablets are indicated for the treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer (mBC) in combination with:

    • an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men, or
    • fulvestrant in patients with disease progression following endocrine therapy